IL-6 and IL-13 in induced sputum of COPD and asthma patients: correlation with respiratory tests.
ABSTRACT IL-6 is strongly implicated in the development of chronic obstructive pulmonary disease (COPD). IL-13 is the well-documented central mediator in allergic asthma. IL-6 is attributed to the proinflammatory activities in COPD as well as asthma. In COPD patients exacerbation is increased by serum IL-6. The association of IL-13 as well as IL-6 with the impaired respiratory function of asthma patients remains controversial.
The aim of this study was to compare the concentration of IL-6 and IL-13 in the induced sputum of asthma and COPD patients, and to assess the possible association of these cytokines with the impairment of lung function.
Twenty-six subjects with COPD and 18 subjects with asthma were enrolled in this study. IL-6 and IL-13 levels were measured in induced sputum by ELISA and correlated with the results of respiratory tests.
The induced sputum of COPD patients had a significantly higher IL-6 level than the sputum of asthma subjects while no significant differences were found in the levels of IL-13. There was a statistically significant negative correlation between IL-6 level and FEV(1) or FEV(1)/FVC in asthma patients (r = -0.59 and -0.54, respectively) and a negative correlation that did not reach statistical significance between IL-6 level and FEV(1), FEV(1)% or FVC in COPD subjects (r = -0.30, -0.30 and -0.38, respectively). There was no relationship between concentrations of IL-13 and impaired respiratory function.
Our results confirmed that IL-6, but not of IL-13, is associated with respiratory disorders in both asthma and COPD patients.
Article: Biomarkers in asthma and COPD[show abstract] [hide abstract]
ABSTRACT: In the recent years, a large number of potential biomarkers for asthma and Chronic Obstructive Pulmonary Disease (COPD) have been described. Biomarkers derive from a variety of sources (bronchioalveolar lavage fluid, sputum, exhaled breath, and blood), provide complementary information to ascertain disease diagnosis, stage, activity/progression and/or treatment responses. The present review highlights the current literature and patents in the field with potential increase in disease control and therapeutic effectiveness to be granted in the near future.Recent Patents on Biomarkers. 05/2013; 3(2):137-144.